MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Atomoxetine (Strattera)

Selected References:

  • Bro SP, et al. 2015. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol; 7:139-47.
  • Bröms G, et al. 2023. Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations: A Multinational Study. J Clin Psychiatry 16, 84(1).
  • Brown JT, et al. 2019. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther; 106(1):94-102.
  • Cohen JM, et al. 2017. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol; 130(6):1192-201.
  • Kallen B, et al. 2013. The Use of Central Nervous System Active Drugs During Pregnancy. Pharmaceuticals; 6(10):1221-86.
  • Naguy A, et al. 2020. Atomoxetine in-focus! Asian J Psychiatr; 49:101634.
  • Perugi G, et al. 2015. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. Expert Opin Pharmacother.;16(14):2193-204.
  • Strattera Product Label. 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0121363e-dcd9-4c24-940b-ea890ab762e7 [accessed 10/2019].

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.